药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
3,7,11,15-tetramethyl-hexadecan-1-ol
Atezolizumab
The risk or severity of adverse effects can be increased when Atezolizumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Ravulizumab
The risk or severity of adverse effects can be increased when Ravulizumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Ixekizumab
The risk or severity of adverse effects can be increased when Ixekizumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Necitumumab
The risk or severity of adverse effects can be increased when Necitumumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Daratumumab
The risk or severity of adverse effects can be increased when Daratumumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Antilymphocyte immunoglobulin (horse)
The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Evolocumab
The risk or severity of adverse effects can be increased when Evolocumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Alirocumab
The risk or severity of adverse effects can be increased when Alirocumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Idarucizumab
The risk or severity of adverse effects can be increased when Idarucizumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Asfotase alfa
The risk or severity of adverse effects can be increased when Asfotase alfa is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Dinutuximab
The risk or severity of adverse effects can be increased when Dinutuximab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Anthrax immune globulin human
The risk or severity of adverse effects can be increased when Anthrax immune globulin human is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Blinatumomab
The risk or severity of adverse effects can be increased when Blinatumomab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Dulaglutide
The risk or severity of adverse effects can be increased when Dulaglutide is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Pembrolizumab
The risk or severity of adverse effects can be increased when Pembrolizumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Siltuximab
The risk or severity of adverse effects can be increased when Siltuximab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Nivolumab
The risk or severity of adverse effects can be increased when Nivolumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Vedolizumab
The risk or severity of adverse effects can be increased when Vedolizumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Secukinumab
The risk or severity of adverse effects can be increased when Secukinumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Obinutuzumab
The risk or severity of adverse effects can be increased when Obinutuzumab is combined with Belantamab mafodotin.